secwatch.observer — SEC 8-K summary
======================================

Issuer:     TREACE MEDICAL CONCEPTS, INC. (TMCI)
CIK:        0001630627
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0000950170-22-023221
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Treace Medical Q3 revenue $33.1M (+53% YoY), raises FY2022 guidance to $135-138M
--------------------------------------------------------------------------------

- Revenue $33.1M, +53% vs Q3 2021; gross margin 80.0% vs 80.4%.
- Net loss $12.1M ($0.22 loss per share); adjusted EBITDA loss $8.2M.
- Full-year 2022 revenue guidance raised to $135-138M from $130-134M (43-46% growth).
- Direct sales channel contributed 74% of revenue vs 53% in Q3 2021.
- Appointed Lance A. Berry and Jane E. Kiernan to Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1630627/000095017022023221/0000950170-22-023221-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1630627/000095017022023221/tmci-20221108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-023221

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer